

Manuel Bardies

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3241367/publications.pdf>

Version: 2024-02-01

153
papers

7,230
citations

117453

34
h-index

58464

82
g-index

155
all docs

155
docs citations

155
times ranked

5898
citing authors

#	ARTICLE	IF	CITATIONS
1	From the target cell theory to a more integrated view of radiobiology in Targeted radionuclide therapy: The Montpellier group's experience. <i>Nuclear Medicine and Biology</i> , 2022, 104-105, 53-64.	0.3	14
2	Modelling SPECT auto-contouring acquisitions for ¹⁷⁷ Lu & ¹³¹ I molecular radiotherapy using new developments in Geant4/GATE. <i>Physica Medica</i> , 2022, 96, 101-113.	0.4	2
3	Scientific Developments in Imaging and Dosimetry for Molecular Radiotherapy. <i>Clinical Oncology</i> , 2021, 33, 117-124.	0.6	8
4	Generation of clinical ¹⁷⁷ Lu SPECT/CT images based on Monte Carlo simulation with GATE. <i>Physica Medica</i> , 2021, 85, 24-31.	0.4	9
5	Advanced Monte Carlo simulations of emission tomography imaging systems with GATE. <i>Physics in Medicine and Biology</i> , 2021, 66, 10TR03.	1.6	82
6	A study of the interplay effect in radiation therapy using a Monte-Carlo model. <i>Physica Medica</i> , 2021, 87, 73-82.	0.4	3
7	A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT/CT imaging performed within the MRTDosimetry project. <i>EJNMMI Physics</i> , 2021, 8, 55.	1.3	34
8	Technical note: GAMMORA, a free, open-source, and validated GATE-based model for Monte-Carlo simulations of the Varian TrueBeam. <i>Physica Medica</i> , 2021, 89, 211-218.	0.4	6
9	Clinical implementation of PLANETÂDose for dosimetric assessment after [¹⁷⁷ Lu]Lu-DOTA-TATE: comparison with Dosimetry ToolkitÂ and OLINDA/EXMÂ V1.0. <i>EJNMMI Research</i> , 2021, 11, 1.	1.1	24
10	Overview of commercial treatment planning systems for targeted radionuclide therapy. <i>Physica Medica</i> , 2021, 92, 52-61.	0.4	19
11	Whole body planar and 3D quantitative imaging after Lu-DOTATATE on CZT SPECT/CT device with MEHRS collimator. First report. <i>Hellenic Journal of Nuclear Medicine</i> , 2021, 24, 165-166.	0.2	0
12	Internal microdosimetry of alpha-emitting radionuclides. <i>Radiation and Environmental Biophysics</i> , 2020, 59, 29-62.	0.6	30
13	The therapeutic effectiveness of ¹⁷⁷ Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. <i>Leukemia</i> , 2020, 34, 1315-1328.	3.3	12
14	Dosimetric methodology for ¹³¹ I therapy for benign thyroid diseases. <i>Medecine Nucleaire</i> , 2020, 44, 261-266.	0.2	1
15	A study of the interplay effect for VMAT SBRT using a fourâ axes motion phantom. <i>Journal of Applied Clinical Medical Physics</i> , 2020, 21, 208-215.	0.8	9
16	Feasibility of intratumoral ¹⁶⁵ Holmium siloxane delivery to induced U87 glioblastoma in a large animal model, the Yucatan minipig. <i>PLoS ONE</i> , 2020, 15, e0234772.	1.1	8
17	Brief progress report from the intersocietal working group on differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1345-1347.	3.3	4
18	OpenDose: Open-Access Resource for Nuclear Medicine Dosimetry. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1514-1519.	2.8	54

#	ARTICLE	IF	CITATIONS
19	Comparison of commercial dosimetric software platforms in patients treated with ¹⁷⁷ Lu- DOTATATE for peptide receptor radionuclide therapy. <i>Medical Physics</i> , 2020, 47, 4602-4615.	1.6	34
20	Monte Carlo dosimetry of a realistic multicellular model of follicular lymphoma in a context of radioimmunotherapy. <i>Medical Physics</i> , 2020, 47, 5222-5234.	1.6	5
21	Setting up a quantitative SPECT imaging network for a European multi-centre dosimetry study of radioiodine treatment for thyroid cancer as part of the MEDIRAD project. <i>EJNMMI Physics</i> , 2020, 7, 61.	1.3	23
22	A semantic database for integrated management of image and dosimetric data in low radiation dose research in medical imaging. <i>AMIA ... Annual Symposium proceedings</i> , 2020, 2020, 492-501.	0.2	1
23	Enabling Large Scale Data Production for OpenDose with GATE on the EGI Infrastructure. , 2019, , .		3
24	Voxel-based dosimetry is superior to mean absorbed dose approach for establishing dose-effect relationship in targeted radionuclide therapy. <i>Medical Physics</i> , 2019, 46, 5403-5406.	1.6	26
25	Relevance and implementation of patient-specific dosimetry in targeted radionuclide therapy. <i>BIO Web of Conferences</i> , 2019, 14, 07001.	0.1	1
26	EP-1788 Dose distribution for electron beam using Monte Carlo simulation with GATE. <i>Radiotherapy and Oncology</i> , 2019, 133, S967-S968.	0.3	0
27	Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 4775-4790.	3.2	26
28	Dosimetry and Toxicity Studies of the Novel Sulfonamide Derivative of Sulforhodamine 101([¹⁸ F]SRF101) at a Preclinical Level. <i>Current Radiopharmaceuticals</i> , 2019, 12, 40-48.	0.3	2
29	PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter?. <i>Journal of Nuclear Medicine</i> , 2018, 59, 747-748.	2.8	58
30	Evaluation of [¹⁸ F]FNM biodistribution and dosimetry based on whole-body PET imaging of rats. <i>Nuclear Medicine and Biology</i> , 2018, 59, 1-8.	0.3	13
31	An innovative in vitro device providing continuous low doses of \hat{I}^3 -rays mimicking exposure to the space environment: A dosimetric study. <i>Life Sciences in Space Research</i> , 2018, 16, 38-46.	1.2	0
32	From fixed activities to personalized treatments in radionuclide therapy: lost in translation?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 152-154.	3.3	34
33	[¹⁸²] Dosimetry in radiopharmaceutical therapy. <i>Physica Medica</i> , 2018, 52, 70.	0.4	0
34	Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [¹⁷⁷ Lu-DOTA0, Tyr3]-octreotate. <i>EJNMMI Research</i> , 2018, 8, 103.	1.1	31
35	[066] EFOMP guidelines on the transposition of EU BSS art.60 in national legislations. <i>Physica Medica</i> , 2018, 52, 26.	0.4	1
36	[OA085] CT Quantification of holmium distribution for absorbed dose calculation in a context of microbrachytherapy. <i>Physica Medica</i> , 2018, 52, 33-34.	0.4	2

#	ARTICLE	IF	CITATIONS
37	Biological and dosimetric evaluation of [¹¹ C]S-adenosyl Methionine as a potential agent for prostate cancer diagnosis. <i>Cancer Research Frontiers</i> , 2018, 4, 27-44.	0.2	1
38	Internal dosimetry with the Monte Carlo code GATE: validation using the ICRP/ICRU female reference computational model. <i>Physics in Medicine and Biology</i> , 2017, 62, 1885-1904.	1.6	27
39	Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details. <i>Journal of Nuclear Medicine</i> , 2017, 58, 862-862.	2.8	8
40	Monte Carlo dose calculation in presence of low-density media: Application to lung SBRT treated during DIBH. <i>Physica Medica</i> , 2017, 41, 46-52.	0.4	15
41	The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1783-1786.	3.3	48
42	Low-energy electron dose-point kernel simulations using new physics models implemented in Geant4-DNA. <i>Nuclear Instruments & Methods in Physics Research B</i> , 2017, 398, 13-20.	0.6	15
43	Abstract ID: 155 OpenDose: A collaborative effort to produce reference dosimetric data with Monte Carlo simulation software. <i>Physica Medica</i> , 2017, 42, 32-33.	0.4	3
44	Voxel-based multimodel fitting method for modeling time activity curves in SPECT images. <i>Medical Physics</i> , 2017, 44, 6280-6288.	1.6	19
45	Optimization of GATE simulations for whole-body planar scintigraphic acquisitions using the XCAT male phantom with ¹⁷⁷ Lu-DOTATATE biokinetics in a Siemens Symbia T2. <i>Physica Medica</i> , 2017, 42, 292-297.	0.4	10
46	PV-0183: Microbrachytherapy: even more localised dose profiles?. <i>Radiotherapy and Oncology</i> , 2017, 123, S93-S94.	0.3	0
47	Clinical outcomes 1 year after empiric ¹³¹ I therapy for hyperthyroid disorders. <i>Nuclear Medicine Communications</i> , 2017, 38, 756-763.	0.5	18
48	Comparison of Empiric Versus Whole-Body/Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 717-722.	2.8	81
49	Realistic multi-cellular dosimetry for ¹⁷⁷ Lu-labelled antibodies: model and application. <i>Physics in Medicine and Biology</i> , 2016, 61, 6935-6952.	1.6	15
50	Which impact of tumor density variations on absorbed dose in external radiotherapy. <i>Physica Medica</i> , 2016, 32, 301.	0.4	2
51	Small scale radiopharmaceutical dosimetry. <i>Physica Medica</i> , 2016, 32, 169.	0.4	0
52	Monte-Carlo dose computation in radiotherapy for lung at very low density. <i>Physica Medica</i> , 2016, 32, 245-246.	0.4	0
53	Patient-specific dosimetry in molecular radiotherapy: Why and how?. <i>Physica Medica</i> , 2016, 32, 193.	0.4	0
54	Implementation of new physics models for low energy electrons in liquid water in Geant4-DNA. <i>Physica Medica</i> , 2016, 32, 1833-1840.	0.4	61

#	ARTICLE	IF	CITATIONS
55	Accelerated GPU based SPECT Monte Carlo simulations. <i>Physics in Medicine and Biology</i> , 2016, 61, 4001-4018.	1.6	14
56	OSSI-PET: Open-Access Database of Simulated ^{11}C Raclopride Scans for the Inveon Preclinical PET Scanner: Application to the Optimization of Reconstruction Methods for Dynamic Studies. <i>IEEE Transactions on Medical Imaging</i> , 2016, 35, 1696-1706.	5.4	3
57	Complex cell geometry and sources distribution model for Monte Carlo single cell dosimetry with iodine 125 radioimmunotherapy. <i>Nuclear Instruments & Methods in Physics Research B</i> , 2016, 366, 227-233.	0.6	11
58	Virtual bolus for total body irradiation treated with helical tomotherapy. <i>Journal of Applied Clinical Medical Physics</i> , 2015, 16, 164-176.	0.8	24
59	TestDose: A nuclear medicine software based on Monte Carlo modeling for generating gamma camera acquisitions and dosimetry. <i>Medical Physics</i> , 2015, 42, 6885-6894.	1.6	12
60	Nonlinearity in MCF7 Cell Survival Following Exposure to Modulated 6 MV Radiation Fields. Dose-Response, 2015, 13, 155932581561075.	0.7	5
61	Model-based versus specific dosimetry in diagnostic context: Comparison of three dosimetric approaches. <i>Medical Physics</i> , 2015, 42, 1288-1296.	1.6	23
62	Application and Dosimetric Requirements for Gallium-68 labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors. <i>PET Clinics</i> , 2015, 10, 477-486.	1.5	14
63	Multi-scale hybrid models for radiopharmaceutical dosimetry with Geant4. <i>Physics in Medicine and Biology</i> , 2014, 59, 7625-7641.	1.6	3
64	Dose point kernels in liquid water: An intra-comparison between GEANT4-DNA and a variety of Monte Carlo codes. <i>Applied Radiation and Isotopes</i> , 2014, 83, 137-141.	0.7	42
65	Biting the magic bullet: celebrating a decade of the EANM Dosimetry Committee. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1-3.	3.3	9
66	Hybrid MicroPET Imaging for Dosimetric Applications in Mice: Improvement of Activity Quantification in Dynamic MicroPET Imaging for Accelerated Dosimetry Applied to 6-[^{18}F]Fluoro-l-DOPA and 2-[^{18}F]Fluoro-l-Tyrosine. <i>Molecular Imaging and Biology</i> , 2014, 16, 383-394.	1.3	6
67	Comparison of Geant4-DNA simulation of S-values with other Monte Carlo codes. <i>Nuclear Instruments & Methods in Physics Research B</i> , 2014, 319, 87-94.	0.6	26
68	A review of the use and potential of the GATE Monte Carlo simulation code for radiation therapy and dosimetry applications. <i>Medical Physics</i> , 2014, 41, 064301.	1.6	332
69	The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1976-1988.	3.3	179
70	Radiopharmaceutical dosimetry: from the animals to the clinics. <i>Physica Medica</i> , 2014, 30, e9.	0.4	0
71	Fractionated ^{90}Y -britumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. <i>Journal of Clinical Oncology</i> , 2014, 32, 212-218.	0.8	57
72	Simulating radial dose of ion tracks in liquid water simulated with Geant4-DNA: A comparative study. <i>Nuclear Instruments & Methods in Physics Research B</i> , 2014, 333, 92-98.	0.6	38

#	ARTICLE	IF	CITATIONS
73	^{99m} TcO ₄ ²⁻ , Auger-Mediated Thyroid Stunning: Dosimetric Requirements and Associated Molecular Events. PLoS ONE, 2014, 9, e92729.	1.1	12
74	Calculating an estimate of tissue integrated activity in ¹⁸ F-FDG PET imaging using one SUV value. EJNMMI Research, 2013, 3, 26.	1.1	6
75	A fast method for rescaling voxel S values for arbitrary voxel sizes in targeted radionuclide therapy from a single Monte Carlo calculation. Medical Physics, 2013, 40, 082502.	1.6	15
76	EFOMP and EANM: joint recommendations for a curriculum for the education and training of physicists in nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 645-648.	3.3	0
77	Defining the role for dosimetry and radiobiology in combination therapies. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 4-5.	3.3	5
78	TestDose: a SPECT image generator for clinical dosimetry studies. , 2013, , .		2
79	Apoptosis and p53 are not involved in the anti-tumor efficacy of ¹²⁵ I-labeled monoclonal antibodies targeting the cell membrane. Nuclear Medicine and Biology, 2013, 40, 471-480.	0.3	28
80	The assessment and management of risks associated with exposures to short-range Auger- and beta-emitting radionuclides. State of the art and proposals for lines of research. Journal of Radiological Protection, 2013, 33, R1-R16.	0.6	12
81	Curriculum for education and training of Medical Physicists in Nuclear Medicine. Physica Medica, 2013, 29, 139-162.	0.4	17
82	Treatment planning in molecular radiotherapy. Zeitschrift Fur Medizinische Physik, 2013, 23, 262-269.	0.6	44
83	Improved realism of hybrid mouse models may not be sufficient to generate reference dosimetric data. Medical Physics, 2013, 40, 052501.	1.6	26
84	Tandem myeloablative ¹³¹ I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients. Immunotherapy, 2013, 5, 1283-1286.	1.0	3
85	Generation of whole-body scintigraphic images with new GATE output capacities. , 2013, , .		1
86	Monte Carlo Methods in Nuclear Medicine. Medical Radiology, 2012, , 759-768.	0.0	1
87	Radiolabeled Antibodies for Cancer Imaging and Therapy. Methods in Molecular Biology, 2012, 907, 681-697.	0.4	61
88	Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients. Tumor Biology, 2012, 33, 679-688.	0.8	48
89	dAcquisition setting optimization and quantitative imaging for ¹²⁴ I studies with the Inveon microPET-CT system. EJNMMI Research, 2012, 2, 7.	1.1	6
90	Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 548-549.	3.3	6

#	ARTICLE	IF	CITATIONS
91	Clinical radioimmunotherapy—the role of radiobiology. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 720-734.	12.5	191
92	EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 192-200.	3.3	156
93	Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 2153-2164.	3.3	25
94	Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine — a review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 2269-2281.	3.3	58
95	Alpha-Particle Microdosimetry. <i>Current Radiopharmaceuticals</i> , 2011, 4, 266-280.	0.3	19
96	EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1238-1250.	3.3	217
97	Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. <i>Cancer</i> , 2010, 116, 1093-1100.	2.0	33
98	R112: Traitement des carcinomes pŕitonaux de petite taille par radioimmunothŕapie Auger flash. <i>Bulletin Du Cancer</i> , 2010, 97, S59.	0.6	0
99	Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing ¹²⁵ I-Labeled Monoclonal Antibodies. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1748-1755.	2.8	23
100	Dosimetry is Alive and Well. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 593-595.	0.7	4
101	Kinetic Model Analysis for Absorbed Dose Calculation Applied to Brain in [18F]-Fluorodeoxyglucose Positron Emission Tomography Imaging. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 665-669.	0.7	8
102	THE GEANT4-DNA PROJECT. <i>International Journal of Modeling, Simulation, and Scientific Computing</i> , 2010, 01, 157-178.	0.9	366
103	Implementation of angular response function modeling in SPECT simulations with GATE. <i>Physics in Medicine and Biology</i> , 2010, 55, N253-N266.	1.6	23
104	Effect of Patient Morphology on Dosimetric Calculations for Internal Irradiation as Assessed by Comparisons of Monte Carlo Versus Conventional Methodologies. <i>Journal of Nuclear Medicine</i> , 2009, 50, 316-323.	2.8	53
105	Impact of Mouse Model on Preclinical Dosimetry in Targeted Radionuclide Therapy. <i>Proceedings of the IEEE</i> , 2009, 97, 2076-2085.	16.4	27
106	EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 2103-2110.	3.3	469
107	Efficient simulations of iodine 131 SPECT scans using GATE. , 2009, , .		2
108	Evidence of Extranuclear Cell Sensitivity to Alpha-Particle Radiation Using a Microdosimetric Model. I. Presentation and Validation of a Microdosimetric Model. <i>Radiation Research</i> , 2009, 171, 657-663.	0.7	25

#	ARTICLE	IF	CITATIONS
109	Comparison of Electron Dose-Point Kernels in Water Generated by the Monte Carlo Codes, PENELOPE, GEANT4, MCNPX, and ETRAN. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 461-467.	0.7	31
110	Evidence of Extranuclear Cell Sensitivity to Alpha-Particle Radiation Using a Microdosimetric Model. II. Application of the Microdosimetric Model to Experimental Results. Radiation Research, 2009, 171, 664-673.	0.7	25
111	SMALL SCALE DOSIMETRY IN NUCLEAR MEDICINE. Radiotherapy and Oncology, 2009, 92, S59-S60.	0.3	0
112	EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1405-1412.	3.3	204
113	Small-Scale Dosimetry: Challenges and Future Directions. Seminars in Nuclear Medicine, 2008, 38, 367-383.	2.5	31
114	Cell Membrane is a More Sensitive Target than Cytoplasm to Dense Ionization Produced by Auger Electrons. Radiation Research, 2008, 170, 192-200.	0.7	99
115	Implementation of cluster analysis in 3D dosimetry for targeted radionuclide therapy. , 2008, , .		0
116	Implementation of a Microdosimetric Model for Radioimmunotherapeutic Alpha Emitters. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 387-392.	0.7	3
117	Implementing Dosimetry in GATE: Dose-Point Kernel Validation with GEANT4 4.8.1. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 125-129.	0.7	34
118	A voxel-based mouse for internal dose calculations using Monte Carlo simulations (MCNP). Physics in Medicine and Biology, 2007, 52, 1013-1025.	1.6	88
119	Nuclear medical imaging using $^{125}\text{I}+^{131}\text{I}$ coincidences from ^{44}Sc radio-nuclide with liquid xenon as detection medium. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2007, 571, 142-145.	0.7	83
120	Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1699-1700.	3.3	39
121	Validation of a personalized dosimetric evaluation tool (Oedipe) for targeted radiotherapy based on the Monte Carlo MCNPX code. Physics in Medicine and Biology, 2006, 51, 601-616.	1.6	60
122	RTNCAT (Real Time NCAT): Implementing Real Time physiological movement of voxelized phantoms in GATE. , 2006, , .		3
123	Optimized radioiodine therapy for Graves' disease: Two MIRD-based models for the computation of patient-specific therapeutic ^{131}I activity. Nuclear Medicine Communications, 2006, 27, 559-566.	0.5	16
124	Use of the GATE Monte Carlo package for dosimetry applications. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2006, 569, 335-340.	0.7	43
125	Quantitative imaging for clinical dosimetry. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2006, 569, 467-471.	0.7	8
126	The Impact of PET and SPECT on Dosimetry for Targeted Radionuclide Therapy. Zeitschrift Fur Medizinische Physik, 2006, 16, 47-59.	0.6	107

#	ARTICLE	IF	CITATIONS
127	COMPUTER TIME (CPU) COMPARISON OF SEVERAL INPUT FILE FORMATS CONSIDERING DIFFERENT VERSIONS OF MCNPX IN CASE OF PERSONALISED VOXEL-BASED DOSIMETRY. , 2006, , .		2
128	EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 855-897.	3.3	467
129	Current developments at IRSN on computational tools dedicated to assessing doses for both internal and external exposure. Radiation Protection Dosimetry, 2005, 115, 522-529.	0.4	13
130	OEDIPE: A Personalized Dosimetric Tool Associating Voxel-Based Models with MCNPX. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 325-332.	0.7	42
131	Dosimetric comparison of Monte Carlo codes (EGS4, MCNP, MCNPX) considering external and internal exposures of the Zubal phantom to electron and photon sources. Radiation Protection Dosimetry, 2005, 116, 631-635.	0.4	11
132	Monte Carlo Modeling of Gamma Cameras for I-131 Imaging in Targeted Radiotherapy. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 77-84.	0.7	49
133	New thermoluminescent dosimeters (TLD): optimization and characterization of TLD threads sterilizable by autoclave. Physics in Medicine and Biology, 2004, 49, 1803-1815.	1.6	5
134	GATE: a simulation toolkit for PET and SPECT. Physics in Medicine and Biology, 2004, 49, 4543-4561.	1.6	1,765
135	Impact of Scatter and Attenuation Corrections for Iodine-131 Two-Dimensional Quantitative Imaging in Patients. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 191-199.	0.7	7
136	Dosimetric Impact of Correcting Count Losses due to Deadtime in Clinical Radioimmunotherapy Trials Involving Iodine-131 Scintigraphy. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 117-124.	0.7	8
137	Correction of count losses due to deadtime on a DST-XLi (SMVi-GE) camera during dosimetric studies in patients injected with iodine-131. Physics in Medicine and Biology, 2002, 47, N79-N90.	1.6	21
138	Comparison of four scatter correction methods for patient whole-body imaging during therapeutic trials with iodine-131. Cancer, 2002, 94, 1224-1230.	2.0	10
139	Dose point-kernels for radionuclide dosimetry. , 2002, , 158-174.		2
140	Production of new thermoluminescent mini-dosimeters. Physics in Medicine and Biology, 2000, 45, 479-494.	1.6	12
141	[131I]-TYR3-octreotide: clinical dosimetry and use for internal radiotherapy of metastatic paraganglioma and carcinoid tumors. Nuclear Medicine and Biology, 2000, 27, 809-813.	0.3	3
142	Dosimetry and Microdosimetry of Targeted Radiotherapy. Current Pharmaceutical Design, 2000, 6, 1469-1502.	0.9	33
143	Cell death induced by a 131I-labeled monoclonal antibody in ovarian cancer multicell spheroids. Nuclear Medicine and Biology, 1996, 23, 623-626.	0.3	6
144	Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 560-567.	2.2	17

#	ARTICLE	IF	CITATIONS
145	Computational methods in radionuclide dosimetry. <i>Physics in Medicine and Biology</i> , 1996, 41, 1941-1955.	1.6	17
146	Pre-clinical and clinical studies of two new bifunctional chelating agents for immunoscintigraphy with ¹¹¹ In-anti-CEA monoclonal antibody. <i>Nuclear Medicine Communications</i> , 1996, 17, 781-789.	0.5	0
147	Bifunctional Antibodies for Radioimmunotherapy. <i>Hybridoma</i> , 1995, 14, 125-128.	0.9	18
148	Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres. <i>Physics in Medicine and Biology</i> , 1994, 39, 961-981.	1.6	81
149	MIBG Scintigraphy of a Patient with Pheochromocytoma on Labetalol Therapy. <i>Clinical Nuclear Medicine</i> , 1992, 17, 308-311.	0.7	11
150	Comparison of technetium-99mC and phytate aerosol in ventilation studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1992, 19, 349-54.	2.2	14
151	Use of multi-cell spheroids of ovarian carcinoma as an intraperitoneal radio-immunotherapy model: Uptake, retention kinetics and dosimetric evaluation. <i>International Journal of Cancer</i> , 1992, 50, 984-991.	2.3	28
152	A simplified approach to alpha dosimetry for small spheres labelled on the surface. <i>Physics in Medicine and Biology</i> , 1990, 35, 1551-1561.	1.6	6
153	A simplified approach to beta dosimetry for small spheres labelled on the surface. <i>Physics in Medicine and Biology</i> , 1990, 35, 1039-1050.	1.6	16